Ovid Therapeutics Inc. (OVID): Nasdaq/NYSE listing notice — Ovid Therapeutics Q2 net loss $4.7M, cash $38.3M; receives Nasdaq extension to Feb 2026

Ovid Therapeutics Inc.

Net loss of $4.7M ($0.06 EPS) vs net income of $8.5M ($0.12 EPS) in Q2 2024.
Revenue from royalty agreements $6.3M (vs $169K), including $7.0M ganaxolone royalty monetization with Immedica.
Cash $38.3M, expected to fund operations into early 2H 2026.
OV329 Phase 1 topline safety/biomarker results anticipated Q3 2025.
Company transferred to Nasdaq Capital Market with extended bid price compliance deadline to Feb 9, 2026.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Ovid Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

August 12, 2025, that the Company’s application to transfer to the Nasdaq Capital Market was approved and the Company is eligible for an additional 180 calendar day period, or until February 9, 2026 (the “Second Compliance Date”), to regain compliance with the minimum bid price requirement. At the opening of business on August 14, 2025, the Company’s common stock will be transferred to the Nasdaq Capital Market, which operates in substantially the same manner as the Nasdaq Global Select Market, where it continues to trade under the symbol “OVID.” The Company intends to monitor the closing bid

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-040007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.